{
    "title": "108_hr1075",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Ephedra Public Protection Act''.\n\nSEC. 2. REQUIREMENT OF PREMARKET APPROVAL FOR DIETARY SUPPLEMENTS \n              CONTAINING EPHEDRINE GROUP ALKALOIDS; REPORTING OF \n              SERIOUS ADVERSE EXPERIENCES.\n\n    (a) In General.--Chapter IV of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 341 et seq.) is amended--\n            (1) in section 402(a)(2), by inserting after ``section 512; \n        or'' the following: ``(D) if it is a dietary supplement that \n        contains any ephedrine group alkaloids and is unsafe within the \n        meaning of section 416; or''; and\n            (2) by adding at the end the following section:\n\n``SEC. 416. EPHEDRINE GROUP ALKALOIDS.\n\n    ``(a) Requirement of Premarket Approval.--A new ephedrine \nsupplement shall be deemed unsafe for purposes of section 402(a)(2)(D) \nunless an approval of an application filed under subsection (b) is \neffective with respect to such supplement.\n    ``(b) Application.--Any person may file with the Secretary an \napplication with respect to a new ephedrine supplement. Not later than \n180 days after the filing of the application, or such additional period \nas may be agreed upon by the Secretary and the applicant, the Secretary \nshall either--\n            ``(1) issue an order under subsection (c) approving the \n        application; or\n            ``(2) issue an order refusing to approve the application, \n        after providing the applicant notice of an opportunity for a \n        hearing before the Secretary.\n    ``(c) Standards.--The Secretary shall approve an application under \nsubsection (b) for a new ephedrine supplement if the application meets \nthe criteria of the Secretary for demonstrating to the Secretary that \nthe supplement does not present a significant or unreasonable risk of \nillness or injury--\n            ``(1) under the conditions of use recommended or suggested \n        in the labeling for the supplement; or\n            ``(2) if no conditions of use are suggested or recommended \n        in the labeling, under ordinary conditions of use.\n    ``(d) Reporting of Serious Adverse Experiences.--\n            ``(1) In general.--Each person who is a manufacturer of \n        ephedrine supplements, or a packer or distributor of the \n        supplements whose name appears on the labeling of the \n        supplement, shall (with respect to such supplements \n        manufactured, packed, or distributed by that person)--\n                    ``(A) investigate each claim of a serious adverse \n                experience of which the person is aware in order to \n                determine whether the claim is a documented incident;\n                    ``(B) investigate each documented incident of such \n                an experience;\n                    ``(C) develop and implement written procedures for \n                investigations of such claims and incidents; and\n                    ``(D) submit to the Secretary in accordance with \n                paragraph (2) notifications and reports regarding such \n                claims and incidents.\n            ``(2) Certain requirements.--\n                    ``(A) Notification of secretary regarding \n                documented incident.--As soon as possible but not later \n                than 30 days after becoming aware of a claim of a \n                serious adverse experience with respect to an ephedrine \n                supplement, the applicable person under paragraph (1) \n                shall determine whether the claim is a documented \n                incident, and if the claim is such an incident, shall \n                submit to the Secretary a notification of  such fact. \nThe notification shall include a copy of the current labeling for the \nsupplement.\n                    ``(B) Report regarding results of investigation.--\n                As soon as possible but not later than 60 days after \n                identifying a documented incident of a serious adverse \n                experience, the applicable person under paragraph (1) \n                shall complete an investigation of the experience and \n                submit to the Secretary a report describing the \n                findings of the investigation, including a finding on \n                whether the ephedrine supplement involved is a causal \n                factor in such experience.\n            ``(3) Duplicative reports.--The Secretary may establish \n        procedures to avoid duplicative reporting under paragraph (1) \n        on an ephedrine supplement by the persons referred to in such \n        paragraph with respect to such supplement, subject to the \n        Secretary establishing requirements to ensure that the \n        Secretary receives notifications and reports within the period \n        of time specified in paragraph (2).\n    ``(e) Applicability of Certain Provisions.--In the case of new \nephedrine supplements, this section applies in lieu of sections \n402(f)(1)(A) and 402(f)(1)(B). In the case of any ephedrine supplement, \nthe two sentences immediately following section 402(f)(1)(D) do not \napply, and section 402(f)(2) does not apply.\n    ``(f) Definitions.--\n            ``(1) Ephedrine supplements.--For purposes of this section:\n                    ``(A) The term `ephedrine supplement' means a \n                dietary supplement containing any ephedrine group \n                alkaloids (as defined in section 201(nn)).\n                    ``(B) The term `new ephedrine supplement' means a \n                dietary supplement containing any new ephedrine group \n                alkaloids (as defined in section 201(nn)).\n            ``(2) Serious adverse experiences.--For purpose of this \n        section:\n                    ``(A)(i) The term `adverse experience', with \n                respect to an ephedrine supplement, means an adverse \n                health-related experience of an individual who ingested \n                the supplement, which experience is alleged by the \n                individual, a family member of the individual, or a \n                treating health professional to be associated with the \n                supplement, whether or not such experience is \n                considered to be related, casually or otherwise, to the \n                supplement by a person referred to in paragraph (1) \n                with respect to the supplement .\n                    ``(ii) The term `serious', with respect to an \n                adverse experience, means any of the following \n                outcomes: Death, a life-threatening condition, \n                inpatient hospitalization, a persistent or significant \n                disability or incapacity, or a congenital anomaly or \n                birth defect.\n                    ``(B) The term `documented incident', with respect \n                to an ephedrine supplement, means a claim of a serious \n                adverse experience that the applicable person under \n                subsection (d)(1) has investigated to the extent of \n                verifying that such an experience did occur, but \n                without investigating the allegation that the \n                experience is associated with the supplement.''.\n    (b) Prohibited Act Regarding Reporting on Serious Adverse \nExperiences.--Section 301 of the Federal Food, Drug, and Cosmetic Act \n(21 U.S.C. 331) is amended by adding at the end the following:\n    ``(hh) The failure of a person to comply with any requirement under \nsection 416(d).''.\n    (c) Definitions.--Section 201 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 321) is amended by adding at the end the \nfollowing:\n    ``(nn)(1)(A) The term `ephedrine group alkaloids', with respect to \na dietary supplement, includes natural ephedrine group alkaloids and \nsynthetic ephedrine group alkaloids.\n    ``(B) The term `natural ephedrine group alkaloids' means ephedrine \ngroup alkaloids present in or extracted from the herb ephedra or any \nother herb that contains ephedrine group alkaloids.\n    ``(C) The term `synthetic ephedrine group alkaloids' means \nephedrine group alkaloids not present in or extracted from the herb \nephedra or any other herb that contains ephedrine group alkaloids.\n    ``(2)(A) The term `new ephedrine group alkaloids' means ephedrine \ngroup alkaloids that are not generally recognized, among experts \ndescribed in clause (B), as having been adequately shown through \nscientific procedures to present no significant or unreasonable risk of \nillness or injury under the conditions of use recommended or suggested \nin labeling, or if no conditions of use are suggested or recommended in \nthe labeling, under ordinary conditions of use.\n    ``(B) The experts referred to in clause (A) are experts qualified \nby scientific training and experience to evaluate whether ephedrine \ngroup alkaloids present no significant or unreasonable risk of illness \nor injury for purposes of such clause.''.\n    (d) Effective Dates.--With respect to section 416 of the Federal \nFood, Drug, and Cosmetic Act (as added by this section):\n            (1) Subsection (a) of such section takes effect upon the \n        expiration of 30 days after the date of the enactment of this \n        Act. With respect to dietary supplements containing any \n        ephedrine group alkaloids, shipments in commercial distribution \n        as of the date of the enactment of this Act are subject to such \n        subsection (a) to the extent determined appropriate by the \n        Secretary of Health and Human Services.\n            (2) Subsection (d) of such section applies with respect to \n        serious adverse experiences occurring on or after the date of \n        the enactment of this Act, except to the extent that the person \n        involved notifies the Secretary of Health and Human Services in \n        writing that the person will not submit an application under \n        subsection (a) of such section and will not be a packer or \n        distributor of dietary supplements containing any ephedrine \n        group alkaloids.\n\nSEC. 3. PROVISIONS REGARDING ADULTERATED OR MISBRANDED SUPPLEMENTS.\n\n    (a) Adulterated Supplements.--\n            (1) Dietary supplements generally; regulations on good \n        manufacturing practice.--\n                    (A) In general.--Not later than 120 days after the \n                date of the enactment of this Act, the Secretary of \n                Health and Human Services shall publish in the Federal \n                Register a proposed rule for good manufacturing \n                practice regulations under section 402(g) of the \n                Federal Food, Drug, and Cosmetic Act.\n                    (B) Conforming amendment.--Section 402(g)(2) of the \n                Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n                342(g)(2)) is amended in the first sentence by striking \n                ``may'' and inserting ``shall'';\n            (2) Ephedrine group alkaloids.--Section 402(g)(2) of the \n        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 342(g)(2)) is \n        amended--\n                    (A) by striking ``(2)'' and inserting ``(2)(A)''; \n                and\n                    (B) by adding at the end the following:\n    ``(B) In the case of dietary supplements containing ephedrine group \nalkaloids, regulations under clause (A) shall require the following:\n            ``(i) The testing of each production lot or batch to ensure \n        the accuracy of the label in stating the total amount of \n        ephedrine group alkaloids contained in the supplement. Such \n        tests shall be made using high performance liquid \n        chromatography testing or other testing approved by the \n        Secretary for purposes of this subclause.\n            ``(ii) A determination of the expiration date of the \n        supplements.\n            ``(iii) The retention of reserve samples from each lot \n        produced, stored under conditions consistent with the labeling \n        of the supplements, until at least one year after the \n        expiration date of the supplements.\n            ``(iv) The implementation of distribution tracking \n        procedures, including the use of lot numbers.''.\n    (b) Misbranded Supplements Containing Ephedrine Group Alkaloids.--\n            (1) In general.--Section 403 of the Federal Food, Drug, and \n        Cosmetic Act (21 U.S.C. 343) is amended by adding at the end \n        the following:\n    ``(w) If it is a dietary supplement containing any ephedrine group \nalkaloids, unless its label bears an expiration date.''.\n            (2) Effective date.--The amendment made by paragraph (1) \n        takes effect upon the effective date of the final rule for good \n        manufacturing practice regulations under section 402(g) of the \n        Federal Food, Drug, and Cosmetic Act."
}